Realizing tangible value from strategic alliances, joint ventures and partnering arrangements
As drug pipelines among major pharmaceutical manufacturers have become less productive, many companies have increasingly sought to establish a variety of partnering arrangements such as strategic alliances and joint ventures with small, innovative biotech companies as a source for new products. Further, the high cost of Research & Development (R&D), risk management considerations as well as market demand, makes it increasingly attractive for industry players to form alliances, often in the form of licensing or co-marketing/co-promotion agreements.
The resulting benefits of these alliances include:
